Navigation Links
InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
Date:2/17/2010

cepted for review by the FDA, and was granted "Priority Review" status with an expected PDUFA action date of May 4, 2010.
  • On February 1, 2010, we reported that the pirfenidone NDA is scheduled to be discussed at the FDA's Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting on March 9, 2010.
  • A Marketing Authorization Application (MAA) for pirfenidone for the treatment of IPF is expected to be submitted to the European Medicines Agency (EMA) in the current quarter.
  • Seven abstracts concerning pirfenidone and IPF have been accepted for presentations at the Annual Meeting of the American Thoracic Society (ATS) in New Orleans, May 14-19, 2010.  

  • RG7227:

    • On January 11, we reported preliminary, top-line results of a Phase 1b multiple-ascending-dose (MAD) study of low doses of once-daily and twice-daily RG7227 co-administered with low-dose ritonavir in combination with standard of care (SOC) for 15 days in treatment-naive HCV-infected patients.  Preliminary data from the first two cohorts of the study indicated that in the presence of SOC, the majority of patients achieved an undetectable level of HCV RNA after 15 days of treatment.  No drug-related serious adverse events have been reported to date.  InterMune and our collaboration partner Roche plan to amend the protocol of the on-going Phase 1b MAD study to evaluate 12 weeks of RG7227 ritonavir-boosted therapy plus SOC.
    • The companies anticipate presenting the results of the MAD ritonavir-boosting study at a medical conference in the first half of 2010, subject to abstract acceptance.
    • Un-blinded 4-week RVR (rapid virologic response) and 12-week EVR (early virologic response) data from the 12-week
      '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
    2. InterMune Announces Start of Phase 1b Trial of ITMN-191
    3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
    4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
    5. InterMune Announces Progress on Pirfenidone in IPF
    6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
    7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
    8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
    9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
    10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
    11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2015)... 1, 2015 - ... R egistry data presented at ESC ... on the evolution of manag ing AF ... -   The first-ever two-year outcomes from the Global ... 2015 expose that all-cause death was the most frequent major event in more ...
    (Date:9/1/2015)... Norway , September 1, 2015 ... biopharmaceutical company, today announces that it has appointed ... as Non-Executive Directors to its Board of Directors, effective ... 30 years of experience in pharma and biotech and ... Genzyme, a Sanofi company. Previously her role was Vice ...
    (Date:8/31/2015)... The Indiana Medical Device Manufacturers Council and ... Sciences Policy Forum to state legislators. The new policy ... Diagnostics in Indianapolis and featured ... Ellspermann and State Sen. Brandt Hershman . ... new Learning & Development Center, which is under construction ...
    Breaking Medicine Technology:Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9BerGenBio Appoints Non-Executive Directors 2Indiana Lt. Gov. Sue Ellspermann and State Sen. Brandt Hershman Kick Off New Life Sciences Policy Series 2Indiana Lt. Gov. Sue Ellspermann and State Sen. Brandt Hershman Kick Off New Life Sciences Policy Series 3
    ... NEW YORK, Jan. 4, 2011 Reportlinker.com announces that a ... Cosmetic Surgery Products http://www.reportlinker.com/p060973/Cosmetic-Surgery-Products.html ... through 2014 Demand for products used in ... to $2.8 billion in 2014, when 16.1 million cosmetic procedures ...
    ... Jan. 3, 2011 Dynatronics Corporation (Nasdaq: ... of an agreement with Premier Purchasing Partners, L.P., the ... contracted supplier of physical therapy products and exercise equipment ... alternate market facilities.   Premier, Inc. is ...
    Cached Medicine Technology:Reportlinker Adds Cosmetic Surgery Products 2Reportlinker Adds Cosmetic Surgery Products 3Dynatronics Named Contract Supplier to Premier, Inc. 2
    (Date:9/1/2015)... ... , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) has once ... Style 50 Report that recognizes companies that provide the best career opportunities for Hispanic ... from number 24 to 21 of the 50 Best Companies for Latinas. The LATINA ...
    (Date:9/1/2015)... ... September 01, 2015 , ... ... to efficiently cure and prevent different malignancies. Some options for cancer treatment ... properties due to which distinctive approach is necessary for effective treatment. Several ...
    (Date:9/1/2015)... ... September 01, 2015 , ... As part of ... Blue Shield of Minnesota (Blue Cross) has announced Doctor On Demand as the ... Francisco, Doctor On Demand provides immediate access to Board Certified physicians or next-day ...
    (Date:9/1/2015)... ... September 01, 2015 , ... Negative pressure wound therapy (NPWT) ... to remove exudates, fluid, and infectious materials to prepare the wound for healing ... devices, and canisters, etc.) is projected to expand continuously through 2021. , Rising ...
    (Date:9/1/2015)... ... September 01, 2015 , ... ... offering the MonaLisa Touch® , an innovative vaginal health laser procedure that ... a new hormone-free treatment for atrophic vaginitis, a condition that causes vaginal dryness, ...
    Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3
    ... high incidence of Hepatitis A cases in Canterbury has prompted ... people have been infected with the deadly virus since December. ... on an average per year. ,The source of ... health reports. There possibility of some association between the three ...
    ... leptin hormone which is mostly produced in fats cells has ... to// Italian researchers. Giuseppe Matarese and colleagues from Università ... a possible way to both prevent and treat MS. ... in the regulation of food intake, metabolism, and the immune ...
    ... have identified a gene which gives rise to bipolar disorder ... found bipolar susceptibility genes, but this is the first time ... the researchers. ,The work might also explain ... more than 30 years, can help patients. But while lithium ...
    ... Professor Lee Kennedy and other medical experts from Townsville's James ... Queensland. ,The authour said that many studies are ... on the queenslanders. Research is mainly done on the obese ... a knoweledge of how the disease can be managed in ...
    ... at the University of Edinburgh in Scotland after an extensive ... is the most effective therapy. ,It is ... severe depression. Scientists say that despite the concerns it has ... the depressed mind. ,This research extended for a ...
    ... have a state-of-the-art heart and lung treatment centre at ... and lung surgery for patients across the west of ... UK, it will also be a national centre for ... procedures a year will be performed at the centre, ...
    Cached Medicine News:Health News:Electroconvulsive Therapy Is The Treatment For Depression 2
    ... 1000 Power Instrument System is a ... versatility and convenience with modular and ... without hand throttle, for use with ... pedal. Accepts all 1000 and 2000 ...
    ... The Brasseler USA™ 2002 Battery Charger is manufactured ... The 2002 Battery Charger can charge up to ... minutes. The 2002 Charger is designed to operate ... there is a malfunction in the operation of ...
    ... diamond shaped teeth set the blade on a straight ... are very sharp, and the cut starts true, dancing ... with minimal force due to the sharp, smooth ground, ... , ,The troughs between the teeth provide ...
    The High Speed Drill handpiece is a well-balanced, high performance drill that provides high speed for,bone sculpting, along with power for difficult osteotomies. Must be used with the 6401-000 foot ...
    Medicine Products: